Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients. / Jakobsen, Lasse H.; Ellin, Fredrik; Smeland, Knut B.; Wästerlid, Tove; Christensen, Jacob H.; Jørgensen, Judit M.; Josefsson, Pär L.; Øvlisen, Andreas K.; Holte, Harald; Blaker, Yngvild N.; Grauslund, Jacob H.; Bjørn, Jon; Molin, Daniel; Lagerlöf, Ingemar; Smedby, Karin E.; Colvin, Katherine; Thanarajasingam, Gita; Maurer, Matthew J.; Habermann, Thomas M.; Song, Kevin W.; Zhu, Katie Y.; Gerrie, Alina S.; Cheah, Chan Y.; El-Galaly, Tarec C.

I: British Journal of Haematology, 2020.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Jakobsen, LH, Ellin, F, Smeland, KB, Wästerlid, T, Christensen, JH, Jørgensen, JM, Josefsson, PL, Øvlisen, AK, Holte, H, Blaker, YN, Grauslund, JH, Bjørn, J, Molin, D, Lagerlöf, I, Smedby, KE, Colvin, K, Thanarajasingam, G, Maurer, MJ, Habermann, TM, Song, KW, Zhu, KY, Gerrie, AS, Cheah, CY & El-Galaly, TC 2020, 'Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients', British Journal of Haematology. https://doi.org/10.1111/bjh.16425

APA

CBE

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC. 2020. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. British Journal of Haematology. https://doi.org/10.1111/bjh.16425

MLA

Vancouver

Author

Jakobsen, Lasse H. ; Ellin, Fredrik ; Smeland, Knut B. ; Wästerlid, Tove ; Christensen, Jacob H. ; Jørgensen, Judit M. ; Josefsson, Pär L. ; Øvlisen, Andreas K. ; Holte, Harald ; Blaker, Yngvild N. ; Grauslund, Jacob H. ; Bjørn, Jon ; Molin, Daniel ; Lagerlöf, Ingemar ; Smedby, Karin E. ; Colvin, Katherine ; Thanarajasingam, Gita ; Maurer, Matthew J. ; Habermann, Thomas M. ; Song, Kevin W. ; Zhu, Katie Y. ; Gerrie, Alina S. ; Cheah, Chan Y. ; El-Galaly, Tarec C. / Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients. I: British Journal of Haematology. 2020.

RIS

TY - JOUR

T1 - Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy

T2 - an international study of 264 real-world patients

AU - Jakobsen, Lasse H.

AU - Ellin, Fredrik

AU - Smeland, Knut B.

AU - Wästerlid, Tove

AU - Christensen, Jacob H.

AU - Jørgensen, Judit M.

AU - Josefsson, Pär L.

AU - Øvlisen, Andreas K.

AU - Holte, Harald

AU - Blaker, Yngvild N.

AU - Grauslund, Jacob H.

AU - Bjørn, Jon

AU - Molin, Daniel

AU - Lagerlöf, Ingemar

AU - Smedby, Karin E.

AU - Colvin, Katherine

AU - Thanarajasingam, Gita

AU - Maurer, Matthew J.

AU - Habermann, Thomas M.

AU - Song, Kevin W.

AU - Zhu, Katie Y.

AU - Gerrie, Alina S.

AU - Cheah, Chan Y.

AU - El-Galaly, Tarec C.

PY - 2020

Y1 - 2020

N2 - Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0·6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0·4 (95% CI: −0·7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.

AB - Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0·6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0·4 (95% CI: −0·7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.

KW - Burkitt lymphoma

KW - immunochemotherapy

KW - prognosis

KW - real-world patients

KW - survival

U2 - 10.1111/bjh.16425

DO - 10.1111/bjh.16425

M3 - Article

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -